Targeted oral pill for EGFR-mutated advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests an oral pill (DZD9008) that targets a specific genetic change in lung cancer called EGFR. If you have this mutation, the drug may shrink your tumor or slow its growth, especially if other treatments have stopped working or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer that has spread to nearby tissues or other parts of the body.
- Your cancer must have a specific EGFR mutation, which can be found with a tissue or blood test.
- You must have had and progressed on or not tolerated standard treatment, unless you have certain mutations and haven't been treated yet.
- You must be well enough to be up and about for at least half of your waking hours (ECOG performance status 0-1).
- You must have at least one tumor that can be measured on a scan.
- You must have adequate liver, kidney, and blood counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two oral targeted drugs for people with advanced non-small cell lung cancer that has an EGFR mutation. It may help if you have already been treated with a third-generation EGFR pill or if you are starting treatment for the first time.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new combination treatment for people with advanced non-small cell lung cancer that has an EGFR mutation. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests an oral drug called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It may be an option for those who have tried other EGFR treatments or are new to treatment.
This trial tests a new targeted therapy (DZD9008) combined with a drug that blocks blood vessel growth (bevacizumab) for people with a specific type of advanced lung cancer (EGFR mutation). The goal is to see if this combination works better than current treatments.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.